Molecular pharmacology of multitarget cyclin-dependent kinase inhibitors in human colorectal carcinoma cells.
Manohar SM, Joshi KS.
Expert Opin Ther Targets · research support, non-u.s. gov't; journal article · DOI 10.1080/14728222.2023.2199924 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för riviciclib. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
17 hitsPromising Anticancer Activity of Multitarget Cyclin Dependent Kinase Inhibitors against Human Colorectal Carcinoma Cells.
Manohar SM, Joshi KS.
Curr Mol Pharmacol · journal article · DOI 10.2174/1874467215666220124125809Nucleic acid binding mechanism of flavone derivative, riviciclib: Structural analysis to unveil anticancer potential.
Ray B, Mehrotra R.
J Photochem Photobiol B · journal article · DOI 10.1016/j.jphotobiol.2020.111990A review on flavones targeting serine/threonine protein kinases for potential anticancer drugs.
Zhao L, Yuan X, Wang J, Feng Y, Ji F, Li Z, Bian J.
Bioorg Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.1016/j.bmc.2019.01.027Discovery and Preclinical Development of IIIM-290, an Orally Active Potent Cyclin-Dependent Kinase Inhibitor.
Bharate SB, Kumar V, Jain SK, Mintoo MJ, Guru SK, Nuthakki VK, Sharma M, Bharate SS, Gandhi SG, Mondhe DM, Bhushan S, Vishwakarma RA.
J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.7b01765Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.
Sonawane YA, Taylor MA, Napoleon JV, Napoleon JV, Rana S, Contreras JI, Natarajan A.
J Med Chem · research support, non-u.s. gov't; review-article; journal article · DOI 10.1021/acs.jmedchem.6b00150A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma.
Cassaday RD, Goy A, Advani S, Chawla P, Nachankar R, Gandhi M, Gopal AK.
Clin Lymphoma Myeloma Leuk · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; journal article; research support, n.i.h., extramural · DOI 10.1016/j.clml.2015.02.021Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Shirsath N, Rathos M, Chaudhari U, Sivaramakrishnan H, Joshi K.
Lung Cancer · research support, non-u.s. gov't; journal article · DOI 10.1016/j.lungcan.2013.08.010Molecular mechanisms of anti-tumor properties of P276-00 in head and neck squamous cell carcinoma.
Mishra PB, Lobo AS, Joshi KS, Rathos MJ, Kumar GA, Padigaru M.
J Transl Med · research-article; journal article · DOI 10.1186/1479-5876-11-42Potentiation of in vitro and in vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells.
Rathos MJ, Khanwalkar H, Joshi K, Manohar SM, Joshi KS.
BMC Cancer · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/1471-2407-13-29P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.
Shirsath NP, Manohar SM, Joshi KS.
Mol Cancer · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/1476-4598-11-77Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers.
Rathos MJ, Joshi K, Khanwalkar H, Manohar SM, Joshi KS.
J Transl Med · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/1479-5876-10-161Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells.
Manohar SM, Padgaonkar AA, Jalota-Badhwar A, Rao SV, Joshi KS.
Prostate Cancer Prostatic Dis · journal article · DOI 10.1038/pcan.2011.51Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription.
Manohar SM, Rathos MJ, Sonawane V, Rao SV, Joshi KS.
Leuk Res · research support, non-u.s. gov't; journal article · DOI 10.1016/j.leukres.2010.12.010Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma.
Raje N, Hideshima T, Mukherjee S, Raab M, Vallet S, Chhetri S, Cirstea D, Pozzi S, Mitsiades C, Rooney M, Kiziltepe T, Podar K, Okawa Y, Ikeda H, Carrasco R, Richardson PG, Chauhan D, Munshi NC, Sharma S, Parikh H, Chabner B, Scadden D, Anderson KC.
Leukemia · research support, non-u.s. gov't; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1038/leu.2008.378In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.
Joshi KS, Rathos MJ, Joshi RD, Sivakumar M, Mascarenhas M, Kamble S, Lal B, Sharma S.
Mol Cancer Ther · journal article · DOI 10.1158/1535-7163.mct-06-0613P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models.
Joshi KS, Rathos MJ, Mahajan P, Wagh V, Shenoy S, Bhatia D, Chile S, Sivakumar M, Maier A, Fiebig HH, Sharma S.
Mol Cancer Ther · journal article · DOI 10.1158/1535-7163.mct-06-0614